… to H 1 antihistamines (H 1 AH) in the POLARIS study (NCT02329223), a randomized, double-…
for omalizumab and IgE, and efficacy and safety data for omalizumab in Japanese patients. …

… The POLARIS study demonstrates that omalizumab is an … omalizumab-treated groups in
the current study had a rapid onset of treatment effect after the first administration of omalizumab…

… Conclusions: This study supports the safety and effectiveness of omalizumab in … in POLARIS
versus 25.0 in the current study.However, unlike POLARIS, patients in this real-world study …

… Omalizumab (Oma) is a therapeutic option for patients with refractory forms of CSU. … of the
POLARIS study 15 and no report of outcomes 16 (Fig. 1). Thus, seven studies were included in …

… This systematic review evaluates the efficacy and safety of omalizumab for chronic … years
old treated with omalizumab for 16 to 40 weeks were evaluated. Omalizumab 150 mg does not …

… • The objective of the POLARIS study was to evaluate the efficacy and safety of omalizumab
in an Eastern Asian population with CIU/CSU who remain symptomatic despite H1AH …

… The current findings validated the results from POLARIS study in demonstrating efficacy of
omalizumab in the treatment of CSU regardless of severity and complication with angioedema…

… on long‐term safety and predictors of effectiveness of omalizumab (anti‐IgE) in chronic
urticaria are lacking. We evaluated the outcome of treatment with omalizumab in a large cohort of …

… studies from Europe, Turkey, and the USA and POLARIS was the first study to evaluate the
safety and efficacy of omalizumab in … POLARIS was a 26-week multi-center study from Korea …

… III POLARIS study found significant decreases in itch severity score for omalizumab versus
… reported an adverse event rate of 4% with omalizumab and a safety profile similar to that …